



肿瘤防治研究

Cancer Research on Prevention and Treatment

请输入检索词

肿瘤防治研究 (<http://www.zlfzyj.com>)

本期目录

(http://www.zlfzyj.com/CN/volumn/volumn_1294.shtml)

◀ 前一篇

临床研究

| 过刊浏览

(<http://www.zlfzyj.com/CN/abstract/abstract4719.shtml>)

(<http://www.zlfzyj.com/CN/article/showOldVolumn.do>) |

| 后一篇 ▶

高级检索

(<http://www.zlfzyj.com/CN/article/advSearchArticle.do>)

(<http://www.zlfzyj.com/CN/abstract/abstract4721.shtml>)

血浆miR-221的表达与乳腺癌患者新辅助化疗疗效的相关性

赵瑞华, 李向柯, 张伟杰

450052 郑州, 郑州大学第一附属医院肿瘤科 河南省高等学校临床医学重点学科开放实验室

Plasma miR-221 Expression could Predict Chemosensitivity to Neoadjuvant#br# Chemotherapy in Breast Cancer Patients

ZHAO Ruihua, LI Xiangke, ZHANG Weijie

Department of Oncology, The First Affiliated Hospital of Zhengzhou University Institute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

摘要 参考文献 相关文章 Metrics

全文: PDF (601 KB) HTML (1 KB)

输出: BibTeX (<http://www.zlfzyj.com/CN/article/getTxtFile.do?fileType=BibTeX&id=4720>) | EndNote (<http://www.zlfzyj.com/CN/article/getTxtFile.do?fileType=EndNote&id=4720>) (RIS)

摘要

目的 探讨血浆中miR-221的表达是否可以作为乳腺癌患者对以紫杉类和蒽环类药物为主的新辅助化疗疗效的预测指标。方法 应用QRT-PCR方法检测以紫杉类和蒽环类为主的新辅助化疗的93例乳腺癌患者和32名健康志愿者血浆miR-221的表达水平,并分析miR-221的表达水平与乳腺癌患者临床病理特征及化疗疗效的关系。结果 (1)与健康志愿者(1.114±0.093)相比,乳腺癌患者血浆miR-221平均水平(1.453±0.065)明显增高(P=0.007)。(2)miR-221表达与患者HR状态显著相关,高miR-221表达的患者倾向于HR表达阴性。(3)miR-221高表达组和低表达组相比,ORR差异有统计学意义,但pCR率差异无统计学意义(ORR:P=0.044;pCR:P=0.477)。结论 miR-221表达水平可能作为对以紫杉和蒽环类为主的新辅助化疗耐药的预测指标。

关键词 : miR-221, 乳腺癌, 新辅助化疗

Abstract :

Objective To explore the possibility of plasma miR-221 as a biomarker for chemosensitivity to neoadjuvant chemotherapy(NAC) in breast cancer patients. Methods The expression levels of circulating plasma miR-221 in 32 healthy individuals and 93 breast cancer patients who received NAC were assessed by QRT-PCR method. The correlation between miR-221 expression levels and clinical pathological features and chemosensitivity were also analysed. Results miR-221 expression levels in the plasma of breast cancer patients(1.453±0.065) were significantly higher than those in healthy individuals (1.114±0.093)(P=0.007). miR-221 expression level was significantly associated with hormone receptor(HR) status (P=0.008). Patients with higher plasma miR-221 levels tended to be with HR-negative. Patients with different miR-221 levels had significant differences in overall response rate (ORR), not complete response (pCR) rate (ORR:P=0.044; pCR: P=0.477). Conclusion Plasma miR-221 expression may be a predictive biomarker for chemosensitivity to NAC in breast cancer patients.

Key words : miR-221 Breast cancer Neoadjuvant chemotherapy

收稿日期: 2013-08-23

ZTFLH: R737.9 (./article/showArticleBySubjectScheme.do?code=R737.9)

基金资助:

郑州大学第一附属医院院内青年基金资助项目(00165)

作者简介: 赵瑞华(1983-)女,博士,主治医师,主要从事乳腺癌及食管癌的内科治疗及基础研究

- ▶ 加入我的书架
- ▶ 加入引用管理器
- ▶ E-mail Alert (<http://www.zlfzyj.com/CN/alert/showAlertInfo.do>)
- ▶ RSS (<http://www.zlfzyj.com/CN/rss/showRssInfo.do>)

作者相关文章

引用本文:

赵瑞华, 李向柯, 张伟杰. 血浆miR-221的表达与乳腺癌患者新辅助化疗疗效的相关性[J]. 肿瘤防治研究, 10.3971/j.issn.1000-8578.2014.10.007.
ZHAO Ruihua, LI Xiangke, ZHANG Weijie. Plasma miR-221 Expression could Predict Chemosensitivity to Neoadjuvant#br# Chemotherapy in Breast Cancer Patients. Cancer Research on Prevention and Treatment, 2014, 41(10): 1087-1092.

链接本文:

<http://www.zlfzyj.com/CN/10.3971/j.issn.1000-8578.2014.10.007> (<http://www.zlfzyj.com/CN/10.3971/j.issn.1000-8578.2014.10.007>) 或
<http://www.zlfzyj.com/CN/Y2014/V41/I10/1087> (<http://www.zlfzyj.com/CN/Y2014/V41/I10/1087>)

鄂ICP备08002248号

版权所有 © 《肿瘤防治研究》编辑部

地址: 武汉市洪山区卓刀泉南路116号

电话: 027-87670126

邮编: 430079

Email: zlfzyjzz@vip.163.com



杂志官网



微信公众号: zlfzyjzz